ClearPoint Neuro, Inc. (CLPT) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
17.96
↑+85% vs avg
5yr avg: 9.68
30Y Low3.7·High106.0
ROE
↓
-95.6%
↑-38% vs avg
5yr avg: -69.5%
30Y Low-283%·High-38%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLPT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ClearPoint Neuro, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $533M | $387M | $416M | $167M | $205M | $233M | $252M | $63M | $17M | $21M | $9M |
| Enterprise Value | $545M | $400M | $399M | $158M | $189M | $191M | $256M | $60M | $18M | $17M | $11M |
| P/E Ratio → | -19.74 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.41 | 10.48 | 13.24 | 6.97 | 9.97 | 14.27 | 19.63 | 5.63 | 2.33 | 2.88 | 1.63 |
| P/B Ratio | 17.96 | 13.82 | 16.37 | 7.89 | 5.55 | 4.77 | 105.95 | 13.77 | 11.35 | 3.65 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CLPT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.81 | 12.72 | 6.59 | 9.21 | 11.71 | 19.94 | 5.34 | 2.38 | 2.29 | 1.83 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CLPT Profitability
Margins and return-on-capital ratios measuring operating efficiency
ClearPoint Neuro, Inc. earns an operating margin of -65.4%. Operating margins have expanded from -93.7% to -65.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -95.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.4% | 61.4% | 60.9% | 56.8% | 65.8% | 68.2% | 71.1% | 64.9% | 66.9% | 60.7% | 54.0% |
| Operating Margin | -65.4% | -65.4% | -62.9% | -93.7% | -79.5% | -82.1% | -48.5% | -41.0% | -71.4% | -85.9% | -130.3% |
| Net Profit Margin | -69.1% | -69.1% | -60.3% | -92.2% | -80.0% | -88.4% | -52.9% | -49.4% | -83.8% | -97.1% | -140.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -95.6% | -95.6% | -81.2% | -76.1% | -38.4% | -56.3% | -194.8% | -181.7% | -167.9% | -282.6% | — |
| ROA | -37.3% | -37.3% | -46.2% | -45.0% | -27.1% | -30.3% | -32.7% | -56.0% | -56.7% | -67.3% | -92.2% |
| ROIC | -73.7% | -73.7% | -142.2% | -101.3% | -86.8% | -150.2% | -120.4% | -212.4% | -235.1% | -506.3% | -982.7% |
| ROCE | -41.7% | -41.7% | -61.6% | -53.5% | -29.8% | -30.7% | -36.2% | -65.9% | -68.4% | -91.3% | -219.2% |
CLPT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $12M ($58M total debt minus $46M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.08 | 2.08 | 0.14 | 0.66 | 0.32 | 0.25 | 10.15 | 0.54 | 2.30 | 0.84 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.44 | -0.65 | -0.43 | -0.42 | -0.86 | 1.69 | -0.70 | 0.25 | -0.75 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.12 | -10.12 | — | — | -201.90 | -13.81 | -3.70 | -4.80 | -5.29 | -7.21 | -6.62 |
CLPT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ClearPoint Neuro, Inc.'s current ratio of 5.91x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 5.13x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 4.87x to 5.91x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.91 | 5.91 | 3.22 | 4.87 | 7.54 | 13.02 | 7.96 | 2.71 | 3.31 | 2.90 | 2.02 |
| Quick Ratio | 5.13 | 5.13 | 2.56 | 3.80 | 6.17 | 11.98 | 6.95 | 1.86 | 2.27 | 2.37 | 1.43 |
| Cash Ratio | 4.27 | 4.27 | 1.94 | 3.11 | 5.52 | 11.38 | 6.28 | 1.49 | 1.54 | 2.11 | 1.10 |
| Asset Turnover | — | 0.38 | 0.80 | 0.56 | 0.37 | 0.25 | 0.43 | 0.94 | 0.94 | 0.53 | 0.78 |
| Inventory Turnover | 1.71 | 1.71 | 1.79 | 1.31 | 0.75 | 1.05 | 1.15 | 1.22 | 1.16 | 1.25 | 1.49 |
| Days Sales Outstanding | — | 71.70 | 54.80 | 60.09 | 47.33 | 52.33 | 53.52 | 35.47 | 61.25 | 46.96 | 54.97 |
CLPT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ClearPoint Neuro, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
| Shares Outstanding | — | $28M | $27M | $25M | $24M | $21M | $16M | $13M | $11M | $8M | $3M |
Peer Comparison
Compare CLPT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLPTYou | $533M | -19.7 | — | — | 61.4% | -65.4% | -95.6% | -73.7% | — |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ABT | $154B | 11.6 | 16.1 | 24.2 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ANGO | $505M | -14.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 ATEC | $1B | -9.2 | 4120.9 | 480.4 | 69.6% | -10.7% | -630.7% | -12.6% | 1425.2 |
 GE | $374B | 43.8 | 38.2 | 51.4 | 36.8% | 19.1% | 45.3% | 24.7% | 2.1 |
 GEHC | $28B | 13.5 | 10.0 | 18.6 | 40.0% | 13.4% | 21.6% | 13.3% | 3.0 |
 SYK | $118B | 36.6 | 21.2 | 27.5 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ISRG | $144B | 51.7 | 39.0 | 58.0 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CLPT — Frequently Asked Questions
Quick answers to the most common questions about buying CLPT stock.
What is ClearPoint Neuro, Inc.'s P/E ratio?
ClearPoint Neuro, Inc.'s current P/E ratio is -19.7x. This places it at the 50th percentile of its historical range.
What is ClearPoint Neuro, Inc.'s ROE?
ClearPoint Neuro, Inc.'s return on equity (ROE) is -95.6%. The historical average is -130.5%.
Is CLPT stock overvalued?
Based on historical data, ClearPoint Neuro, Inc. is trading at a P/E of -19.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are ClearPoint Neuro, Inc.'s profit margins?
ClearPoint Neuro, Inc. has 61.4% gross margin and -65.4% operating margin.